AVXL

Anavex Life Sciences Corp

Add to Watchlist

Advanced Chart

11.170

-0.19(-1.673%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

11.625

Open

11.440

VWAP

11.23

Vol

759.94K

Mkt Cap

953.60M

Low

10.930

Amount

8.53M

EV/EBITDA(TTM)

Total Shares

84.64M

837.83M

EV/OCF(TTM)

P/S(TTM)

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.100

-28.57%

-0.145

+3.57%

-0.145

+3.57%

Estimates Revision

The market is revising No Change the revenue expectations for Anavex Life Sciences Corp. (AVXL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 19.98%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-13.85%

In Past 3 Month

Stock Price

Go Up

+19.98%

In Past 3 Month

2 Analyst Rating

155.15% Upside

Wall Street analysts forecast AVXL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVXL is 28.50 USD with a low forecast of 15.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

155.15% Upside

Current: 11.170

Low

15.00

Averages

28.50

High

42.00

155.15% Upside

Current: 11.170

Low

15.00

Averages

28.50

High

42.00

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$42

2025-04-07

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$42

2025-04-07

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$46

2025-04-07

Reason

D. Boral Capital

Jason Kolbert

Price Target

$46

2025-04-07

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$42

2025-03-31

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$42

2025-03-31

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$42

2025-02-18

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$42

2025-02-18

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$46

2025-02-12

Reason

D. Boral Capital

Jason Kolbert

Price Target

$46

2025-02-12

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$42

2025-01-28

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$42

2025-01-28

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Anavex Life Sciences Corp (AVXL.O) is -22.72, compared to its 5-year average forward P/E of -15.09. For a more detailed relative valuation and DCF analysis to assess Anavex Life Sciences Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-15.09

Current PE

-22.72

Overvalued PE

-6.84

Undervalued PE

-23.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.51

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.62

Undervalued EV/EBITDA

-11.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

146.08

Current PS

0.00

Overvalued PS

562.41

Undervalued PS

-270.24